Tecentriq 1 875 mg solution for injection

DRUG2 trials

Sponsors

Oslo University Hospital HF, Isala Klinieken Stichting

Conditions

CancerInflammatory bowel diseaseOncologyRheumatic disease

Phase 2

Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

RecruitingCTIS2023-507894-16-00

Oslo University Hospital HFCancer

Start: 2021-04-01Target: 6000Updated: 2026-01-22

Phase 4

Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)

Not yet recruitingCTIS2024-518878-14-01

Isala Klinieken StichtingInflammatory bowel disease, Oncology, Rheumatic disease

Target: 1261Updated: 2025-12-18